Comparative Pharmacology
Head-to-head clinical analysis: DYNACIN versus SOLODYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNACIN versus SOLODYN.
DYNACIN vs SOLODYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dynacin (minocycline) is a semi-synthetic tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to mRNA-ribosome complex. It also has anti-inflammatory and neuroprotective effects via inhibition of microglial activation, matrix metalloproteinases, and p38 MAPK signaling.
Solodyn (minocycline hydrochloride) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
100 mg orally twice daily or 200 mg orally once daily.
1 mg/kg orally once daily as extended-release tablets; not to exceed 100 mg/day. Alternatively, 1 mg/kg orally once daily as immediate-release tablets; not to exceed 100 mg/day.
None Documented
None Documented
Terminal elimination half-life 18-24 hours; prolonged in renal impairment (up to 50 hours in severe insufficiency). Steady state achieved in 4-5 days.
Terminal elimination half-life: 11-22 hours (mean ~16 hours). Clinically, steady-state reached in 3-4 days; half-life prolonged in renal impairment.
Renal (40-50% unchanged), hepatic metabolism (30-40% as metabolites), fecal (<10%).
Primarily renal (40-70% unchanged) via glomerular filtration; significant biliary/fecal (20-30%) as unchanged drug and metabolites. Enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic